Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eucommia bark, the dried bark of *Eucommia ulmoides* Oliver, is a staple of Traditional Chinese Medicine (TCM) known as Du Zhong. It is traditionally used to tonify the liver and kidneys and strengthen the bones and muscles. In modern clinical research, such as trials conducted by Guizhou Medical University, it is being investigated for its potential to treat endemic skeletal fluorosis, a condition caused by excessive fluoride intake. The bark contains bioactive constituents like lignans (e.g., pinoresinol diglucoside), iridoids, and phenolics, which exhibit osteoprotective, anti-inflammatory, and antioxidant properties. Its therapeutic effect in fluorosis is believed to involve the regulation of bone remodeling and the reduction of oxidative stress in bone tissue.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on eucommia bark.